Lightpath Webview:Layout 1 23/4/10 14:26 Page 1
‘Your Spectroscopy Specialist’
UV-VIS-NIR-IR SAMPLE CELLS FOR USE WITH ALL TYPES OF SPECTROMETERS & FLUORIMETERS
www.lightpathoptical.com
LABORATORY PLANNING SOLUTIONS HEMCO
®
Laboratory Planning
ISO 9001:2015 Certifi ed Company SEFA Certifi edVisit:
HEMCOcorp.com WEBSITE ADVERTISING UV-VIS-NIR-IR
TO ADVERTISE YOUR WEBSITE PLEASE CONTACT:
SALES@INTLABMATE.COM
SAMPLE CELLS FOR
USE WITH ALL TYPES OF SPECTROMETERS & FLUORIMETERS
www.lightpathoptical.com ‘Your Spectroscopy Specialist’
CONSUMABLES & SPARE PARTS
CALIBRATION & REPAIR INSTRUMENTS SAMPLE CELLS ‘Your Spectroscopy Specialist’ Solutions
UniFlow SE AireStream Laboratory Fume Hoods Unitized Superstructure for total chemical resistance Full line of Laboratory Cabinets & Epoxy Worksurfaces
UV-VIS-NIR-IR SAMPLE CELLS FOR USE WITH ALL TYPES OF SPECTROMETERS & FLUORIMETERS
www.lightpathoptical.com TEMPERATURE CONTROL
PROCESS OPTIMISATION IN PERFECTION Unistats® – Specialists for your lab reactor
Unistats can thermally control your reactor system safely, quickly and reproducibly. Unistats are extremely efficient and easy to operate. More than 50 models allow a reliable scale-up from laboratory to production.
www.huber-online.com
Inspired by temperature
Streamlining Sample Prep for Prostate Cancer Screening
LynxDx, a diagnostics laboratory in Michigan specialising in prostate cancer screening and risk prediction, has successfully incorporated liquid handling solutions from Integra Biosciences into their sample preparation process. Originally utilised for high-throughput COVID-19 testing, these innovative products have now been seamlessly transitioned to support prostate cancer screening, signifi cantly enhancing result accuracy, turnaround times, and ultimately contributing to timely diagnosis and treatment.
LynxDx employs its proprietary MyProstateScore 2.0 (MPS2) approach, a non-invasive urine test that detects 18 genetic biomarkers associated with prostate cancer, for their screening procedures. MPS2 utilises a customised algorithm to optimise diagnostic precision, offering clinical fl exibility for biopsy- naïve patients and those with prior negative biopsies. This cutting-edge approach delivers highly accurate and specifi c insights, reducing the need for unnecessary and potentially high-risk biopsies.
In early 2020, LynxDx adopted Integra’s VIAFLO 96 handheld electronic pipettes and VOYAGER adjustable tip spacing pipettes to facilitate rapid and accurate sample handling during high-volume COVID-19 testing. Dr Jacob Meyers, Senior Scientist of Research and Development at LynxDx, emphasised the selection of Integra’s pipettes due to their robustness and reliability in handling large quantities of diverse saliva samples. These versatile instruments played a pivotal role in maintaining short turnaround times for COVID-19 testing while gradually resuming cancer screening operations.
“We’re already using the VOYAGER pipettes in our cancer screening workfl ow, and we’re currently performing validation of the VIAFLO 96 pipettes for this application,” stated Dr Meyers. “We’d also like to acquire additional Integra products in the near future, as these pipetting solutions will allow us to further streamline and automate our liquid handling workfl ows in preparation for the diagnostic needs of the future.”
More information online:
ilmt.co/PL/X1DV 60534pr@reply-direct.com
Index of Advertisers Azure Biosystems
37
Biopharma Process Systems (BTL) 39 Endecotts Ltd GL Sciences BV Hiden Analytical HTA Srl
25 12
OFC, 45 8
Integra Biosciences AG JSB Group
35 11
Merck 27 Metrohm AG
MicroSolv Technology Corp Myron L Company
17 9
23
Porvair Sciences
Shimadzu Europa GmbH VICI AG
13
IFC 7
Wiggens Technology (Beijing) Co, Ltd 31 WWEM OBC
INTERNATIONAL LABMATE - JULY 2023
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
